| INTELLIA THERAPEUTICS |
| USA |
| Gesundheit |
| US45826J1051 / A2AG6H |
| 38I (Frankfurt) / NTLA (NASDAQ) |
| FRA:38I, ETR:38I, 38I:GR, NASDAQ:NTLA |
| - |
| https://www.intelliatx.co.. |
|
Intellia Therapeutics Inc. is a biotechnology company focused on the development of gene-editing technologies. Specifically, the company leverages CRISPR/Cas9 technology to design therapies aimed at t..
>Volltext.. |
| 1316.94 Mio. EUR |
| 964.75 Mio. EUR |
| 48.74 Mio. EUR |
| -389.49 Mio. EUR |
| -377.69 Mio. EUR |
| -3.61 EUR |
| 83 Mio. EUR |
| 163.84 Mio. EUR |
| -347.9 Mio. EUR |
| 5.45 |
| 26.69% |
| 19.01% |
| - |
| - |
| - |
| - |
| INTELLIA |
| 27.02.26 |
|
||||
|